JP2023545588A5 - - Google Patents

Info

Publication number
JP2023545588A5
JP2023545588A5 JP2023547753A JP2023547753A JP2023545588A5 JP 2023545588 A5 JP2023545588 A5 JP 2023545588A5 JP 2023547753 A JP2023547753 A JP 2023547753A JP 2023547753 A JP2023547753 A JP 2023547753A JP 2023545588 A5 JP2023545588 A5 JP 2023545588A5
Authority
JP
Japan
Application number
JP2023547753A
Other languages
Japanese (ja)
Other versions
JPWO2022079290A5 (https=
JP2023545588A (ja
JP7850460B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/078696 external-priority patent/WO2022079290A2/en
Publication of JP2023545588A publication Critical patent/JP2023545588A/ja
Publication of JPWO2022079290A5 publication Critical patent/JPWO2022079290A5/ja
Publication of JP2023545588A5 publication Critical patent/JP2023545588A5/ja
Application granted granted Critical
Publication of JP7850460B2 publication Critical patent/JP7850460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547753A 2020-10-16 2021-10-15 ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用 Active JP7850460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20202417.0 2020-10-16
EP20202417 2020-10-16
PCT/EP2021/078696 WO2022079290A2 (en) 2020-10-16 2021-10-15 Cullin ring ubiquitin ligase compounds and uses thereof

Publications (4)

Publication Number Publication Date
JP2023545588A JP2023545588A (ja) 2023-10-30
JPWO2022079290A5 JPWO2022079290A5 (https=) 2024-11-08
JP2023545588A5 true JP2023545588A5 (https=) 2024-11-08
JP7850460B2 JP7850460B2 (ja) 2026-04-23

Family

ID=72964476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547753A Active JP7850460B2 (ja) 2020-10-16 2021-10-15 ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用

Country Status (7)

Country Link
US (1) US20240132485A1 (https=)
EP (1) EP4229037A2 (https=)
JP (1) JP7850460B2 (https=)
CN (1) CN116568671A (https=)
AU (1) AU2021359129A1 (https=)
CA (1) CA3194868A1 (https=)
WO (1) WO2022079290A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN116003424B (zh) * 2022-11-30 2024-03-19 中国药科大学 Shp2与mek1双靶点抑制剂及其制备方法与应用
JP2026501188A (ja) * 2022-12-16 2026-01-14 杭州阿諾生物医薬科技有限公司 サイクリンk分解剤及びその使用
WO2025040546A1 (en) * 2023-08-18 2025-02-27 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025104236A1 (en) * 2023-11-15 2025-05-22 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
CN119707806B (zh) * 2024-12-24 2025-12-12 河南师范大学 可见光催化不对称反应制备手性2-氮杂芳烃酰胺的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CN1169520C (zh) 1997-09-29 2004-10-06 耐科塔医药公司 多孔微粒及其使用方法
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
KR20020060160A (ko) * 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
WO2001038309A1 (en) * 1999-11-24 2001-05-31 Cor Therapeutics, Inc. β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
PY0117895A (es) * 2000-07-31 2003-11-03 Pfizer Prod Inc Derivados de imidazol
IL154016A0 (en) * 2000-08-31 2003-07-31 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
EP1256578B1 (en) * 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
AU2007312165A1 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
WO2008061796A2 (en) * 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2309855A4 (en) * 2008-07-30 2012-06-27 Oncotherapy Science Inc BENZIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3-BETA INHIBITORS CONTAINING THE SAME
CA2806766C (en) * 2010-07-28 2017-01-10 Neugen Pharma Inc. Novel amino imidazole compounds selectively suppress oxidative stress induced neurodegeneration
GB2513403A (en) * 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
CA2934700A1 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
JP6195684B2 (ja) * 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd ピラゾール化合物及びt型カルシウムチャンネルブロッカーとしてのそれらの使用
GB2533421A (en) * 2014-12-19 2016-06-22 Nordic Semiconductor Asa Integrated circuits
US10202376B2 (en) * 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104447733B (zh) * 2015-01-05 2016-08-17 中国药科大学 1-苄基-2-吡咯啉酮-4-酰胺类化合物及其制备方法与应用
GB201501870D0 (en) * 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
JP2020503363A (ja) * 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
EP3638664A1 (en) * 2017-06-14 2020-04-22 European Molecular Biology Laboratory Benzofuran amides and heteroaromatic analogues thereof for use in therapy
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
WO2019152437A1 (en) * 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
ES3032327T3 (en) * 2019-01-29 2025-07-17 Foghorn Therapeutics Inc Compounds and uses thereof
CN113330000B (zh) * 2019-01-31 2024-12-24 辉瑞公司 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2022523074A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2023545588A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)